Method for Improving Affinity of Antibody for Antigen and Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 17/154,297, filed Jan 21, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,795,237 | Method for Improving Affinity of Antibody for Antigen and Use Thereof In force · High confidence | Sysmex Corporation | In force | High confidence | ||
| US 12,116,419 | Method for Improving Affinity of Antibody for Antigen and Use Thereof In force · Medium confidence | Sysmex Corporation | In force | Medium confidence | ||
| US 12,122,849 | Method for Improving Affinity of Antibody for Antigen and Use Thereof In force · High confidence | Sysmex Corporation | In force | High confidence | ||
| US 12,139,552 | Method for Improving Affinity of Antibody for Antigen and Use Thereof In force · High confidence | Sysmex Corporation | In force | High confidence | ||
| Application 18/157,739 | Method for Improving Affinity of Antibody for Antigen and Use Thereof Abandoned Abandoned Sep 17, 2024 | Sysmex Corporation | Abandoned | Abandoned Sep 17, 2024 | ||
| Application 18/189,997 | Method for Improving Affinity of Antibody for Antigen and Use Thereof Abandoned Abandoned Oct 11, 2024 | Sysmex Corporation | Abandoned | Abandoned Oct 11, 2024 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Sysmex Corporation.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.